J Biomed 2017; 2:34-38. doi:10.7150/jbm.17794 This volume Cite
Short Research Communication
Correlation Pattern of Serum Lipid Parameters and a Biological Anti-Oxidant Potential Between Premenopausal and Perimenopausal Healthy Women
1. Jui-Tung Chen Clinic, Tokyo, Japan,
2. Division of Community and Family Medicine, Jichi Medical University, Tochigi, Japan
Objectives. Improved understanding of the associations among cardiometabolic, antioxidative, and menopausal status is crucial to prevent cardiovascular disease (CVD). For preventing the development of CVD in women, the association of serum lipid profile and antioxidant parameters during menopausal transition is of interest. The aim of the study is to evaluate the correlation between lipid and antioxidant levels especially in premenopausal and perimenopausal women.
Methods. A total of 130 CVD-free healthy women; the premenopausal group (n = 51, mean 41 years) and perimenopausal group (n = 79, mean 49 years) were studied. A biological antioxidant potential (BAP) test was utilized for measuring antioxidant levels. The association between lipid and BAP levels was examined by linear correlation analyses.
Results. The perimenopausal group showed a significantly higher low-density lipoprotein cholesterol (LDL-C) level than the premenopausal group (mean 123 vs. 111 mg/dL, p < 0.05), while there were no significant differences in triglyceride, high-density lipoprotein cholesterol and BAP levels between the groups. A significant inverse correlation existed between LDL-C and BAP levels in the perimenopausal group (β = -0.30, p < 0.05), but not in the premenopausal group.
Conclusions. The correlation patterns between lipid parameters and antioxidant levels demarcated the premenopausal from perimenopausal stage. Increased LDL-C associated with decreased antioxidant levels in perimenopausal women may call early attention for cardiovascular health.
Keywords: antioxidants, estrogen, FSH, LDL cholesterol, perimenopause
A cardiovascular disease (CVD) risk in premenopausal women was well documented to be lower than postmenopausal women . One possible explanation for it is due to the sex hormonal changes during menopausal transition , and another is due to the alteration of serum lipid profile, for instance an increase of low-density lipoprotein (LDL) cholesterol (LDL-C) [3-5]. Acceleration of atherogenic lipid profile is currently recognized among postmenopausal women, and so in preventing CVD, there is an increasing importance on understanding the characteristics of lipid profile especially at earlier stages of menopausal transition such as perimenopause . Little information is, however, available about the characteristics especially in perimenopausal women. In particular, antioxidant conditions were not sufficiently mentioned as a part of the pathophysiology of CVD development in perimenopausal women .
In general, antioxidant conditions are known to be associated with the CVD development  and positively associated with symptoms and clinical manifestations related to menopause . Recently, a biological antioxidant potential (BAP) test has been used as an easy handling and reliable assay in the clinical setting to measure total antioxidant capacity, which can identify the ability to reduce ferric ions to ferrous ions [8, 9]. The BAP test are widely recognized and used in clinical studies just as the ferric-reducing ability plasma assay  and the test is used to study oxidative stress-related diseases . Given an importance to discuss the association between blood lipid profile and BAP levels besides generic CVD-related parameters during menopausal transition for preventing CVD development, the present study aimed to investigate their correlation patterns between premenopausal and perimenopausal healthy women.
A total of 130 Japanese women, who were diagnosed in the premenopausal group (n = 51, mean 41 years) and in perimenopausal group (n = 79, mean 49 years) were enrolled in this study. The study was approved by the institutional ethics committee and informed consent was obtained from all subjects. Subjects were recruited from women who were visiting our clinic for general medical examinations. Eligible subjects were healthy with no history of CVD, acute infectious disease, or severe liver/kidney disease, and were non-smokers, who were not taking medications including antioxidant supplements. Body mass index (BMI), mean blood pressure (MBP) and blood parameters were measured during a fasting period. Blood was sampled from premenopausal women during the follicular phase.
For a precise determination of menopausal status, subjects were diagnosed into premenopausal and perimenopausal groups based on the classification of the Stages of Reproductive Aging Workshop (STRAW) . According to the classification, the premenopausal group corresponded to the reproductive stage (Stage -3), and the perimenopausal group corresponded to the early and late menopausal transition stage (Stage -2 to -1).
The serum levels of LDL-C, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), estradiol (E2) and follicle-stimulating hormone (FSH) were measured with standard methods. Hemoglobin A1c (HbA1c) level was measured with a high-performance liquid chromatographic method. These analyses were supplied in a single laboratory facility certified in Japanese laboratory system (Mitsubishi BCL Laboratory Co. Ltd., Tokyo, Japan). The BAP tests were implemented by the Free Radical Analytical System (Diacron, Grosseto, Italy) according to the analytical manual. In brief, a 20 μL of blood sample was dissolved in a colored solution obtained by mixing a source of ferric ions (FeCl3, ferric chloride) with a chromogenic substrate (a sulphur-derived compound). After a 5-minute incubation, the intensity of the discolored change was assessed by a photometer, and the amount of reduced ferric ions calculated. The BAP unit was expressed as mol/L of reduced Fe/L.
The difference between the groups was examined by student t-test. A simple correlation between outcome (lipid parameters) and other variables was examined by a Pearson's correlation test, and subsequently, a stepwise multiple regression analysis was performed in order to extract the variables correlated with outcome variables (lipid parameters). The data of TG, E2 and FSH were log-transformed for these analyses because of their skewed distributions. A p-value < 0.05 was considered significant.
As listed in Table 1, the perimenopausal group showed a significantly higher level of age, MBP, LDL-C, HbA1c and FSH, as well as a significantly lower level of E2, than the premenopausal group. There were no significant differences in TG, HDL-C and the BAP levels between the groups.
As listed in Table 2, simple correlation tests and stepwise multiple-regression analyses revealed a significant positive correlation between LDL-C and TG or HbA1c levels in the perimenopause group. Furthermore, there found to be a significant inverse correlation between LDL-C and BAP levels in the perimenopause group. Any relative significant correlations of LDL-C with other parameters were not observed in the premenopause group.
Similar analyses revealed a significant positive correlation between TG and LDL-C, as well as a significant inverse correlation between TG and HDL-C levels in the perimenopause group. Any relative significant correlations of TG with other parameters were not observed in the premenopause group.
Similar analyses revealed a significant positive correlation between HDL-C and FSH, as well as a significant inverse correlation between HDL-C and BMI or TG levels in the perimenopause group. Any relative significant correlations of HDL-C with other parameters were not observed in the premenopause group.
The present study investigated the association of serum lipid parameters with the BAP, besides generic CVD-related parameters, in premenopausal and perimenopausal healthy women. While most correlations between lipid parameters and generic CVD-related parameters were as expected, the significant inverse correlation pattern between LDL-C and BAP levels was found in perimenopausal women, but not in premenopausal women. This seems to demarcate a potential antioxidant linkage with the CVD development between the premenopausal and perimenopausal stage.
A high blood cholesterol, especially LDL-C, concentration is a CVD risk . The incident CVD after menopause can be partly induced by changes in the blood lipid levels that occur following menopausal transition . In the present study, of note, an inverse correlation between LDL-C and BAP levels was found only in the perimenopausal stage. While the increased trend of LDL-C with menopausal transition was also observed in the present study, this appears to be consistent with the result that such an increase level of LDL-C is significantly associated with damage to antioxidant molecules . Even though the LDL-C level was not so high in perimenopausal women of the present study, speculatively, LDL-C and/or LDL particle might be oxidatively modified under the perimenopausal state . Importantly, the present study finding may also provide a proper timing for the management of LDL-C levels in women .
|Parameter||Premenopausal group||Perimenopausal group||P|
|(n = 51)||(n = 79)|
|Age, years||41 ± 6||49 ± 3||< 0.01**|
|BMI, kg/m2||20.9 ± 2.8||21.1 ± 3.2||0.74|
|MBP, mmHg||89 ± 12||95 ± 15||< 0.01**|
|LDL-C, mg/dL||111 ± 32||123 ± 32||0.04*|
|TG, mg/dL||79 (58-106)||85 (62-123)||0.19|
|HDL-C, mg/dL||71 ± 15||73 ± 12||0.52|
|HbA1c, %||5.2 ± 0.3||5.3 ± 0.3||0.02*|
|BAP, μM||1995 ± 238||2026 ± 198||0.43|
|Estradiol, pg/mL||78 (50-128)||43 (15-97)||< 0.01**|
|FSH, mIU/mL||5.6 (3.3-8.9)||30.0 (9.5-70.3)||< 0.01**|
BMI: body mass index, MBP: mean blood pressure, LDL-C: low-density lipoprotein cholesterol, TG: triglyceride, HDL-C: high-density lipoprotein cholesterol, HbA1c: hemoglobin A1c, BAP: biological anti-oxidant potential, FSH: follicular stimulating hormone.
Statistical significance (t-test): P < 0.05. Data are the mean ± standard deviation or the median (inter-quartile range).
Correlations between lipid and other parameters
|Premenopausal group||Perimenopausal group||Premenopausal group||Perimenopausal group||Premenopausal group||Perimenopausal group|
|r (P)||β (P)||r (P)||β (P)||r (P)||β (P)||r (P)||β (P)||r (P)||β (P)||r (P)||β (P)|
|Age, years||0.28 (0.05)||0.26 (0.06)||0.07 (0.54)||NE||0.25 (0.08)||0.19 (0.20)||0.06 (0.60)||NE||-0.05 (0.75)||NE||0.05 (0.64)||0.10 (0.30)|
|BMI, kg/m2||-0.01 (0.98)||NE||0.14 (0.22)||NE||0.16 (0.26)||NE||0.05 (0.66)||NE||-0.30 (0.04*)||-0.23 (0.10)||-0.43 (< 0.01**)||-0.39 (< 0.01**)|
|MBP, mmHg||-0.06 (0.68)||NE||0.10 (0.39)||NE||0.07 (0.63)||NE||0.10 (0.39)||NE||-0.11 (0.46)||NE||-0.09 (0.48)||NE|
|LDL-C, mg/dL||-||-||-||-||0.20 (0.16)||0.19 (0.19)||0.43 (< 0.01**)||0.36 (< 0.01**)||0.19 (0.18)||0.23 (0.10)||-0.09 (0.44)||NE|
|TG, mg/dL||0.20 (0.16)||NE||0.43 (< 0.01**)||0.27 (< 0.01**)||-||-||-||-||-0.20 (0.16)||-0.18 (0.19)||-0.23 (0.04*)||-0.25 (0.02*)|
|HDL-C, mg/dL||0.19 (0.18)||NE||-0.09 (0.44)||NE||-0.20 (0.16)||-0.23 (0.11)||-0.23 (0.04*)||-0.23 (0.03*)||-||-||-||-|
|HbA1c, %||0.20 (0.16)||0.18 (0.19)||0.48 (< 0.01**)||0.38 (< 0.01**)||0.04 (0.81)||NE||0.20 (0.09)||NE||0.08 (0.50)||NE||0.08 (0.50)||0.12 (0.23)|
|BAP, μM||-0.19 (0.19)||NE||-0.36 (< 0.01**)||-0.30 (< 0.01**)||-0.18 (0.20)||NE||-0.21 (0.06)||NE||-0.15 (0.30)||NE||0.24 (0.03*)||0.12 (0.24)|
|Estradiol, pg/mL||-0.01 (0.92)||NE||-0.31 (< 0.01**)||NE||0.14 (0.30)||NE||-0.25 (0.03*)||-0.18 (0.11)||-0.25 (0.08)||-0.17 (0.23)||-0.17 (0.14)||NE|
|FSH, mIU/mL||-0.03 (0.86)||NE||0.22 (0.05)||0.14 (0.13)||-0.14 (0.32)||NE||0.16 (0.16)||NE||0.11 (0.45)||NE||0.31 (< 0.01**)||0.23 (0.03*)|
NE: not extracted, BMI: body mass index, MBP: mean blood pressure, LDL-C: low-density lipoprotein cholesterol, TG: triglyceride, HDL-C: high-density lipoprotein cholesterol,HbA1c: hemoglobin A1c, BAP: biological anti-oxidant potential, FSH: follicular stimulating hormone.
Statistical significance: p < 0.05. Data are r-coefficients (by a Pearson's correlation test) and β-coefficients (by a stepwise multiple regression analysis). Triglyceride, estradiol, and FSH levels were log-transformed in these analyses because of their skewed distributions.
An increase of LDL-C can be caused by not only a simple biological aging but an alteration of sex hormones with menopausal transition , and the change in sex hormones is assumed to affect the correlation between LDL-C and BAP levels. A reduction of LDL-C was, indeed, documented in subjects with hormone replacement therapy using exogenous estrogens . In the preset study, E2 was not significantly extracted as an independent parameter of LDL-C. This might be partially due to a significant but small increase of LDL-C in perimenopausal women relative to that in premenopausal women in the present study.
A decrease of antioxidative conditions can also stem from an alteration of sex hormones during menopausal transition, and blood antioxidant capacity and antioxidant enzyme expression at a gene level were documented to positively correlate with E2 levels [16-18]. On the other hand, the association between (anti)oxidative stress-related markers and sex hormones has been still controversially reported; that is, urinary isoprostane excretion was not correlated with endogenous estrogen levels in perimenopausal women  or total antioxidant ability was not correlated with E2 levels during menopausal transition . In the present study, expectedly, perimenopausal women exhibited a lower level of E2 than premenopausal women, while BAP levels were not significantly correlated with E2 both in premenopausal and perimenopausal women. Our present results were likely to coincide with the later studies [19, 20]. The discrepant results might be due to the difference in (anti)oxidative stress-related marker types measured across studies (the BAP test reflects a global antioxidative condition [8, 9] and there are currently few studies using this test). There is also a thought that the blood E2 level is much lower than the necessary concentration of chemical antioxidants . Thus, the relationship between the antioxidant system and E2 levels has to be more investigated in humans.
The beneficial effect of hormone replacement therapy on the CVD development in earlier stages of menopausal transition was reported [22, 23]; however, there is currently no full explanation and a long-term debate about the benefit and risk for CVD by hormone replacement therapy [24, 25]. Although our present study showed no apparent significant correlation between E2 and LDL-C or BAP levels, further investigations on changes in various biochemical factors, including lipids and (anti)oxidative stress-related markers, by hormone replacement therapy may provide relevant consideration of the therapeutic effect on the CVD development.
The present study had several limitations. The sample size was relatively small, the study design was cross-sectional, and CVD outcomes were not evaluated. While a single anti-oxidant biomarker was used in the present study, comparative studies using the other anti-oxidant biomarkers would be interesting. A prospective study in a larger population with long-term follow-up periods and/or intervention trail with various anti-oxidant biomarkers and antioxidants would be necessary to confirm the results of the present study.
In conclusion, the present study investigated the association of serum lipid parameters with the BAP level between premenopausal and perimenopausal healthy women. There was an increase of LDL-C associated with antioxidant conditions in perimenopausal women, and this might present us to require early attention for the management of cardiovascular health from this stage.
The authors have declared that no competing interest exists.
1. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J. 2005;26:1358-1361
2. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110
3. Fukami K, Koike K, Hirota K, Yoshikawa H, Miyake A. Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. Maturitas. 1995;22:193-197
4. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke. 2001;32:1104-1111
5. White RE, Gerrity R, Barman SA, Han G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids. 2010;75:788-793
6. Kim CJ, Kim TH, Ryu WS, Ryoo UH. Influence of menopause on high density lipoprotein-cholesterol and lipids. J Korean Med Sci. 2000;15:380-386
7. Chen JT, Kotani K. An inverse relation between the Simplified Menopausal Index and biological antioxidant potential. Climacteric. 2013;16:288-291
8. Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M. et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica. 2001;86:85-91
9. Jansen EH, Ruskovska T. Comparative analysis of serum (anti)oxidative status parаmeters in healthy persons. Int J Mol Sci. 2013;14:6106-6115
10. Kim JH, Baik HW, Yoon YS, Joung HJ, Park JS, Park SJ. Measurement of antioxidant capacity using the biological antioxidant potential test and its role as a predictive marker of metabolic syndrome. Korean J Intern Med. 2014;29:31-39
11. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S. STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19:387-395
12. Paik JK, Chae JS, Kang R, Kwon N, Lee SH, Lee JH. Effect of age on atherogenicity of LDL and inflammatory markers in healthy women. Nutr Metab Cardiovasc Dis. 2013;23:967-372
13. Uzun H, Benian A, Madazli R, Topçuoğlu MA, Aydin S, Albayrak M. Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia. Gynecol Obstet Invest. 2005;60:195-200
14. Perrone G, Brunelli R. Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view. Ther Apher Dial. 2013;17:162-168
15. Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S. A Pooled analysis of the effects of conjugated estrogens/bazedoxifene on lipid parameters in postmenopausal women from the selective estrogens, menopause, and response to therapy (SMART) trials. J Clin Endocrinol Metab. 2015;100:2329-2338
16. Massafra C, Gioia D, De Felice C, Picciolini E, De Leo V, Bonifazi M, Bernabei A. Effects of estrogens and androgens on erythrocyte antioxidant superoxide dismutase, catalase and glutathione peroxidase activities during the menstrual cycle. J Endocrinol. 2000;167:447-452
17. Serviddio G, Loverro G, Vicino M, Prigigallo F, Grattagliano I, Altomare E, Vendemiale G. Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J Clin Endocrinol Metab. 2002;87:2843-2848
18. Bellanti F, Matteo M, Rollo T, De Rosario F, Greco P, Vendemiale G. et al. Sex hormones modulate circulating antioxidant enzymes: impact of estrogen therapy. Redox Biol. 2013;1:340-346
19. Sowers M, McConnell D, Jannausch M, Randolph JF, Brook R, Gold EB. et al. Oestrogen metabolites in relation to isoprostanes as a measure of oxidative stress. Clin Endocrinol (Oxf). 2008;68:806-813
20. Cervellati C, Pansini FS, Bonaccorsi G, Bergamini CM, Patella A, Casali F. et al. 17β-estradiol levels and oxidative balance in a population of pre-, peri-, and post-menopausal women. Gynecol Endocrinol. 2011;12:1028-1032
21. Borrás C, Gambini J, Gómez-Cabrera MC, Sastre J, Pallardó FV, Mann GE, Viña J. 17beta-oestradiol up- regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NF kappa B cascade. Aging Cell. 2005;4:113-118
22. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al; WHI, WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356:2591-25602
23. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd. et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15-23
24. Gungor F, Kalelioglu I, Turfanda A. Vascular effects of estrogen and progestins and risk of coronary artery disease: importance of timing of estrogen treatment. Angiology. 2009;60:308-317
25. White RE, Gerrity R, Barman SA, Han G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids. 2010;75:788-793
Corresponding author: Jui-Tung Chen, MD, PhD; J.T. Chen Clinic, 2-13-5 Akasaka, Akasaka-Kaikan B1F, Minato-Ku, Tokyo 107-0052, Japan, Tel: +81-3-5856-0015, Fax: +81-3-5856-0016, E-mail: chin-clzaq.ne.jp